Type 2 Diabetes Patients Taking ACTOS (Pioglitazone HCl) 22% Less Likely To Be Hospitalized For Heart Attack Than Those Taking Rosiglitazone
A total of 29 911 eligible patients were identified in the database; 14 807 in the ACTOS® and 15 104 in the rosiglitazone group. At baseline, the ACTOS® and rosiglitazone groups were well balanced, with the exception of statin and fibrate use, which was higher in the ACTOS® group, consistent with the higher prevalence of hyperlipidemia observed in this group. After adjusting for all known factors influencing the baseline risk of the patients (baseline covariates), the Hazard Ratio (HR) was 0.78 (95%CI: 0.63-0.96) for hospitalization for acute myocardial infarction in favour of Actos®, i.e. a 22% lower risk than for rosiglitazone.
These observations are consistent with the results seen in the landmark placebo-controlled PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study. All studies conducted for the past 10 years, including those in both humans and animals, have shown no evidence that ACTOS® is associated with an increase in risk of heart attack or stroke. Since the introduction of ACTOS® in August 1999, almost 70 million prescriptions have been written, covering more than 8 million patients and 4.5 million patient years.
About ACTOS®
ACTOS® was originally approved by the European Medicines Agency for the treatment of type-2 diabetes in October 2000, the original label was most recently extended in January 2007. In Europe, ACTOS® is indicated in the treatment of type 2 diabetes mellitus:
as monotherapy
- in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance
as dual oral therapy in combination with
- metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin
- a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.
as triple oral therapy in combination with
- metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance
About COMPETACT®
COMPETACT® was first launched in Europe in October 2006.
COMPETACT® 15mg/850mg tablets containing 15mg pioglitazone as hydrochloride and 850mg of metformin hydrochloride. Indication: Treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
About Takeda in Europe
Takeda Pharmaceuticals Europe Limited, based in London, UK, supervises the overall business activities of Takeda's subsidiaries in Europe through promoting pan-European strategies.
Takeda Pharmaceutical Company Limited, located in Osaka, Japan, is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, www.takeda.com
ACTOS® (pioglitazone HCl) is a registered trademark of Takeda Pharmaceutical Company Limited.
http://www.takeda.com
View drug information on ACTOS.
Diabetului de tip 2 pacienþii care iau ACTOS (Pioglitazone HCl) 22% mai puþin susceptibile de a fi Hospitalized Pentru atac de cord decat cei care au luat Rosiglitazone - Type 2 Diabetes Patients Taking ACTOS (Pioglitazone HCl) 22% Less Likely To Be Hospitalized For Heart Attack Than Those Taking Rosiglitazone - articole medicale engleza - startsanatate